New insider activity at Arcutis Biotherapeutics ( (ARQT) ) has taken place on November 5, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In recent transactions involving Arcutis Biotherapeutics stock, key executives have made significant sales. Patrick Burnett, EVP and Chief Medical Officer, sold 2,622 shares for a total of $64,799. Meanwhile, President and CEO Todd Franklin Watanabe parted with 11,547 shares, amounting to $285,373. Additionally, Masaru Matsuda, SVP GC and Corporate Secretary, sold 7,208 shares, bringing in $178,138.
Recent Updates on ARQT stock
Arcutis Biotherapeutics has seen significant developments recently, with the company announcing the commercial launch of ZORYVE cream for treating mild to moderate atopic dermatitis in young children, and the publication of positive long-term safety data for ZORYVE foam in a clinical dermatology journal. These announcements have been complemented by a new awareness campaign featuring Tori Spelling to highlight the burden of inflammatory skin diseases. These developments, alongside strong Q3 earnings and an Investor Day presentation outlining potential peak sales for Zoryve, have led to increased confidence among analysts. Consequently, major financial institutions such as Goldman Sachs, Mizuho, and H.C. Wainwright have raised their price targets for Arcutis Biotherapeutics, citing the company’s growth prospects and sales potential as key factors.
Spark’s Take on ARQT Stock
According to Spark, TipRanks’ AI Analyst, ARQT is a Neutral.
Arcutis Biotherapeutics’ overall score is driven by strong earnings call results and technical indicators, despite challenges in financial performance and valuation. The company’s strategic initiatives and revenue growth are promising, but profitability and cash flow management remain areas for improvement.
To see Spark’s full report on ARQT stock, click here.
More about Arcutis Biotherapeutics
YTD Price Performance: 64.90%
Average Trading Volume: 2,083,944
Technical Sentiment Signal: Buy
Current Market Cap: $2.94B